IBRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImmunityBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$8.42−0.76 (-8.28%)
Close on Oct 19, 2026
- Market cap
- $8.84B
- P/E (TTM)
- –
- Dividend yield
- –
ImmunityBio, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $50.67M | $44.17M | $38.27M | $31.78M | $26.42M | $16.51M | $7.21M | $5.95M | $990.00K | $0 | $0 | $0 | 98.9% | +91.8% |
| Other revenues | $568.00K | $39.00K | $13.00K | $281.00K | $4.00K | $8.00K | $346.00K | $152.00K | $57.00K | $40.00K | $139.00K | $82.00K | 1.1% | +14100.0% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $50.72M | $44.18M | $38.27M | $31.80M | $26.43M | $16.52M | $7.22M | $5.99M | $996.00K | $15.00K | – | – | 99.0% | +91.9% |
| Europe | $518.00K | $24.00K | $16.00K | $262.00K | $0 | $0 | $335.00K | $120.00K | $51.00K | $25.00K | – | – | 1.0% | – |
From the segment and revenue-disaggregation notes of ImmunityBio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.